Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma
Sponsor: Celgene
Listed as NCT00688415, this PHASE1 trial focuses on Advanced Solid Tumors and Lymphoma and remains completed. Sponsored by Celgene, it has been updated 8 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
For direct contact, visit the study record on ClinicalTrials.gov .